Today: 10 November 2025
Subscribe
Browse Category

NASDAQ:BEAM News 20 October 2025 - 2 November 2025

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) reuters.com. (Nasdaq closes on Oct 31 showed ~$63.99 reuters.com.) Over the past month CRSP has gained roughly 17% genengnews.com, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced genengnews.com. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative investing.com. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals investing.com, but the
2 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside. Beam’s stock jumped sharply after the FDA awarded priority designations to its gene-editing therapies. On Oct 20,
21 October 2025
 ·  ·  ·  ·  · 
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Stock Rallies on Technical Breakout Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the day finviz.com. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart – the stock’s 50-day moving average recently rose above its 200-day average finviz.com, a technical signal often seen as confirmation of a positive trend reversal. Zacks noted that BEAM had rallied ~6.8% over the prior four weeks leading into this golden-cross
20 October 2025
 ·  ·  ·  ·  · 
Go toTop